Recce Pharmaceuticals (ASX:RCE) secured approval from the Human Research Ethics Committee to investigate the use of the Recce 327 topical gel in a phase 3 trial in patients with diabetic foot ulcers, according to a Monday filing with the Australian bourse.

The receipt of the approval means the company met the safety and efficacy testing required to proceed with the large-scale trial.

The 12-month trial will be conducted in Indonesia, with regulatory submission anticipated for late 2025, the filing said.

The company's shares closed up more than 3% Monday.

Price (AUD): $0.49, Change: $+0.02, Percent Change: +3.19%